Palisade Bio

Palisade Bio plans to enroll the first patient in the Phase‑2 study ASCENTRA‑UC in the second half of 2026 and expects primary efficacy readouts in the second half of 2027. The company also plans to file an IND with the FDA for a Phase‑2 Crohn’s disease study in H2 2026. Earlier Phase‑1 data showed clinical responses in five ulcerative colitis patients (two remissions) and in the Crohn’s cohort an average SES‑CD reduction of ~47.5% (two patients with endoscopic response and remission). In Q2 2026 Palisade Bio reported a net loss of $10.6 million, increased R&D expenses of $7.4 million and cash of $125.2 million, which it says should be sufficient to fund through the expected Phase‑2 readouts. » Altro su de.investing.com

The FDA has approved the IND application for PALI-2108, allowing Palisade Bio to start the global phase‑2 study ASCENTRA‑UC in moderate to severe ulcerative colitis. The randomized, double‑blind, placebo‑controlled dose‑finding trial will evaluate about 204 patients in North America and Europe (15 mg and 30 mg once daily) with the primary endpoint of clinical remission at week 12; first patient enrollments are planned for H2 2026 and primary efficacy readouts are expected in H2 2027. PALI-2108 is an oral prodrug of a PDE4 inhibitor with selective activation in the terminal ileum and colon; Palisade is working with CRO PSI on the program and plans to file an IND for ASCENTRA‑CD (Crohn’s disease) in H2 2026. » Altro su de.investing.com

Palisade Bio has appointed Robert Baltera and Jordan Zwick to its board of directors; both bring extensive experience in biotech company building, strategic transactions and capital markets. The clinical-pharma company develops oral PDE4 inhibitor prodrugs, with lead program PALI-2108 preparing for Phase 2 studies. Palisade reports a strong balance sheet with more cash than debt and a market capitalization of $281 million; the stock is down 29% year-to-date but up 156% year-over-year and is currently rated overvalued by InvestingPro. » Altro su de.investing.com